Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct-Acting Antiviral agents

作     者：Giovanni Damiani Chiara Franchi Paolo Pigatto Andrea Altomare Alessia Pacifico Stephen Petrou Sebastiano Leone Maria Caterina Pace Marco Fiore 

作者机构：Study Center of Young Dermatologists Italian Network (YDIN) Gised Bergamo Italy and Clinical Dermatology IRCCS Galeazzi Orthopaedic Institute Department of Biomedical Surgical and Dental Sciences University of Milan Clinical Dermatology IRCCS Galeazzi Orthopaedic Institute San Gallicano Dermatological Institute IRCCS Department of Emergency Medicine St. George’s University Medical School Division of Infectious Diseases "San Giuseppe Moscati" Hospital Department of Anesthe-siological Surgical and Emergency Sciences University of Campania "Luigi Vanvitelli" 

出 版 物：《World Journal of Hepatology》 (世界肝病学杂志（英文版）（电子版）)

年 卷 期：2018年第10卷第2期

页      面：329-336页

学科分类：1002[医学-临床医学] 10[医学] 

主　　题：Hepatitis C virus New Direct-Acting Antiviral agents Psoriasis Biological disease modifying drugs 

摘      要：AIM To evaluate the outcomes in biological treatment and quality of life of psoriatic patients with chronic hepatitis C(CHC) treated with new Direct-Acting Antiviral agents(DAAs) compared to pegylated interferon-2α plus ribavirin(P/R) *** This is a retrospective study involving psoriatic patients in biological therapy who underwent anti-hepatitis C virus(HCV) treatment at the Department of Dermatology Galeazzi Orthopaedic Institute Milan, Italy from January 2010 to November 2017. The patients were divided into two groups: patients that underwent therapy with DAAs and patients that underwent HCV treatment with P/R. Patients were assessed by a dermatologist for psoriasis symptoms, collecting Psoriasis Area Severity Index(PASI) scores and the Dermatology Quality of Life Index(DLQI). PASI and DLQI scores were evaluated 24 wk after the end of HCV treatment and were assumed as an outcome of the progression of psoriasis. Switching to a different b DMARD was considered as an inadequate response to biological therapy. The dropout of HCV therapy and sustained virological response(SVR) were considered as outcomes of HCV *** Fifty-nine psoriatic patients in biological therapy underwent antiviral therapy for CHC. Of this, 27 patients were treated with DAAs and 32 with P/R. After 24 wk post treatment, the DLQI and the PASI scores were significantly lower(P 0.001 and P 0.005, respectively) in the DAAs group compared with P/R group. None of the patients in the DAAs group(0/27) compared to 8 patients of the P/R group(8/32) needed a shift in biological *** DAAs seem to be more effective and safe than P/R in HCV-positive psoriatic patients on biological treatment. Fewer dermatological adverse events may be due to interferon-free therapy.